PL3484915T3 - Nowe przeciwciała swoiście wiążące się z epitopami wirusa zika i ich zastosowania - Google Patents

Nowe przeciwciała swoiście wiążące się z epitopami wirusa zika i ich zastosowania

Info

Publication number
PL3484915T3
PL3484915T3 PL17742985.9T PL17742985T PL3484915T3 PL 3484915 T3 PL3484915 T3 PL 3484915T3 PL 17742985 T PL17742985 T PL 17742985T PL 3484915 T3 PL3484915 T3 PL 3484915T3
Authority
PL
Poland
Prior art keywords
specifically binding
zika virus
antibodies specifically
novel antibodies
virus epitopes
Prior art date
Application number
PL17742985.9T
Other languages
English (en)
Inventor
Davide Corti
Original Assignee
Humabs Biomed Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed Sa filed Critical Humabs Biomed Sa
Publication of PL3484915T3 publication Critical patent/PL3484915T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL17742985.9T 2016-07-13 2017-07-12 Nowe przeciwciała swoiście wiążące się z epitopami wirusa zika i ich zastosowania PL3484915T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2016/066684 WO2018010789A1 (en) 2016-07-13 2016-07-13 Novel antibodies specifically binding to zika virus epitopes and uses thereof
PCT/EP2017/067581 WO2018011283A1 (en) 2016-07-13 2017-07-12 Novel antibodies specifically binding to zika virus epitopes and uses thereof

Publications (1)

Publication Number Publication Date
PL3484915T3 true PL3484915T3 (pl) 2024-03-25

Family

ID=56413654

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17742985.9T PL3484915T3 (pl) 2016-07-13 2017-07-12 Nowe przeciwciała swoiście wiążące się z epitopami wirusa zika i ich zastosowania

Country Status (31)

Country Link
US (3) US11117954B2 (pl)
EP (2) EP3484915B1 (pl)
JP (2) JP7252888B2 (pl)
KR (1) KR102595764B1 (pl)
CN (2) CN109563157B (pl)
AU (1) AU2017297757B2 (pl)
BR (1) BR112018074456A2 (pl)
CA (1) CA3024374A1 (pl)
CL (2) CL2019000067A1 (pl)
CO (1) CO2019001111A2 (pl)
CR (1) CR20190066A (pl)
DK (1) DK3484915T5 (pl)
DO (2) DOP2019000006A (pl)
EA (1) EA201990243A1 (pl)
EC (1) ECSP19009170A (pl)
ES (1) ES2959883T3 (pl)
FI (1) FI3484915T3 (pl)
HR (1) HRP20231196T1 (pl)
HU (1) HUE063272T2 (pl)
IL (1) IL262710B2 (pl)
LT (1) LT3484915T (pl)
MX (1) MX2019000526A (pl)
MY (1) MY190553A (pl)
PE (1) PE20190398A1 (pl)
PH (1) PH12018502348B1 (pl)
PL (1) PL3484915T3 (pl)
SG (1) SG11201809879WA (pl)
SI (1) SI3484915T1 (pl)
UA (1) UA126381C2 (pl)
WO (2) WO2018010789A1 (pl)
ZA (1) ZA201807467B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11946017B2 (en) 2016-07-13 2024-04-02 Evonik Operations Gmbh Method of separating lipids from a lysed lipids containing biomass
CR20210094A (es) 2016-10-13 2021-03-31 Massachusetts Inst Technology ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ENVOLTURA DEL VIRUS ZIKA Y USOS DE LOS MISMOS (Divisional 2019-0193)
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
EP3527664A1 (en) 2018-02-15 2019-08-21 Evonik Degussa GmbH Method of isolating lipids from a lipids containing biomass
JP2019152666A (ja) * 2018-03-02 2019-09-12 富士レビオ株式会社 ジカウイルスを検出する方法及びキット
CA3098373A1 (en) 2018-04-24 2019-10-31 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following zikv infection or vaccination
WO2019219396A1 (en) 2018-05-15 2019-11-21 Evonik Operations Gmbh Method of isolating lipids from a lysed lipids containing biomass by emulsion inversion
RU2760575C1 (ru) 2018-05-15 2021-11-29 Эвоник Оперейшнс Гмбх Способ выделения липидов из содержащей липиды биомассы с помощью гидрофобного диоксида кремния
WO2020061159A1 (en) * 2018-09-20 2020-03-26 Vanderbilt University Human antibodies to zika virus
WO2020078568A1 (en) 2018-10-19 2020-04-23 Humabs Biomed Sa Antibodies and methods for treatment of lyssavirus infection
BR112021008217A2 (pt) * 2018-10-31 2021-08-17 Icahn School Of Medicine At Mount Sinai anticorpos humanos que têm como alvo vírus zika ns1, polipeptídeos ns1 e seus usos
JP7463366B2 (ja) * 2018-11-20 2024-04-08 タケダ ワクチン，インコーポレイテッド 新規の抗ジカウイルス抗体及びその使用
WO2020245663A1 (en) * 2019-06-01 2020-12-10 Institut Pasteur Nanobody-based ns1 assay for the specific diagnosis of acute zika virus infection
WO2021050989A1 (en) 2019-09-13 2021-03-18 Duke University Zika antibodies and their use
BR112022008865A2 (pt) * 2019-11-07 2022-09-20 Inst Microbiology Cas Vacina contra zika/dengue e aplicações da mesma.
WO2021101739A1 (en) * 2019-11-19 2021-05-27 Vanderbilt University Human antibodies that neutralize zika virus and methods of use therefor
CN111100201B (zh) * 2019-12-31 2021-09-28 武汉班科生物技术股份有限公司 针对寨卡病毒囊膜蛋白的鼠源单克隆抗体
CN111138534B (zh) * 2019-12-31 2021-09-28 武汉班科生物技术股份有限公司 寨卡病毒囊膜蛋白的鼠源单克隆抗体
JP7471555B2 (ja) * 2020-02-20 2024-04-22 国立感染症研究所長 フラビウイルス交差中和抗体及び医薬組成物
WO2021236225A1 (en) 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
JP2023527169A (ja) 2020-05-20 2023-06-27 タケダ ワクチン，インコーポレイテッド 抗原の効力を決定するための方法
JP2023526493A (ja) 2020-05-20 2023-06-21 タケダ ワクチン，インコーポレイテッド ジカウイルス特異的抗体の検出方法
WO2022001803A1 (zh) * 2020-06-28 2022-01-06 神州细胞工程有限公司 一种降低病毒ade效应的方法
US20240180969A1 (en) * 2021-04-01 2024-06-06 A2 Biotherapeutics, Inc. Polypeptides targeting hla-a*11 and methods of use thereof
CN112921124B (zh) * 2021-04-08 2021-09-28 广东创晟控股集团有限公司 一种快速检测病毒的试剂盒
WO2024211789A1 (en) * 2023-04-07 2024-10-10 Fred Hutchinson Cancer Center Cross-flavivirus binding domains and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US7785799B2 (en) 2002-08-16 2010-08-31 The Board Of Regents Of The University Of Texas System Compositions and methods related to flavivirus envelope protein domain III antigens
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
CA2530388A1 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
US20090252729A1 (en) 2007-05-14 2009-10-08 Farrington Graham K Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto
NZ592036A (en) 2008-10-22 2012-12-21 Inst Research In Biomedicine Methods for producing antibodies from plasma cells
US9822166B2 (en) * 2013-03-15 2017-11-21 Dana-Farber Cancer Institute, Inc. Flavivirus neutralizing antibodies and methods of use thereof
KR20180127397A (ko) 2016-03-11 2018-11-28 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 생약독화된 지카 바이러스 백신
US20170298119A1 (en) * 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
TW201815821A (zh) 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
US11046698B2 (en) 2017-07-28 2021-06-29 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof

Also Published As

Publication number Publication date
IL262710A (en) 2018-12-31
CL2021002994A1 (es) 2022-09-09
JP7252888B2 (ja) 2023-04-05
PH12018502348A1 (en) 2019-03-25
WO2018010789A1 (en) 2018-01-18
US20190256582A1 (en) 2019-08-22
IL262710B1 (en) 2024-01-01
CA3024374A1 (en) 2018-01-18
DK3484915T3 (da) 2023-10-09
MX2019000526A (es) 2019-05-02
CR20190066A (es) 2019-09-10
EP3484915A1 (en) 2019-05-22
CN109563157A (zh) 2019-04-02
UA126381C2 (uk) 2022-09-28
ECSP19009170A (es) 2019-02-28
EP4342911A1 (en) 2024-03-27
ZA201807467B (en) 2024-04-24
KR102595764B1 (ko) 2023-10-30
AU2017297757B2 (en) 2024-06-13
JP2023062036A (ja) 2023-05-02
HUE063272T2 (hu) 2024-01-28
PE20190398A1 (es) 2019-03-13
CO2019001111A2 (es) 2019-08-20
LT3484915T (lt) 2023-10-10
WO2018011283A1 (en) 2018-01-18
CN116199775A (zh) 2023-06-02
SI3484915T1 (sl) 2024-02-29
JP2019533425A (ja) 2019-11-21
US20210355198A1 (en) 2021-11-18
AU2017297757A1 (en) 2018-11-22
US11117954B2 (en) 2021-09-14
HRP20231196T1 (hr) 2024-01-19
ES2959883T3 (es) 2024-02-28
FI3484915T3 (fi) 2023-11-15
BR112018074456A2 (pt) 2019-03-19
PH12018502348B1 (en) 2024-02-28
IL262710B2 (en) 2024-05-01
EA201990243A1 (ru) 2019-07-31
CN109563157B (zh) 2023-01-17
SG11201809879WA (en) 2018-12-28
DK3484915T5 (da) 2024-09-02
CL2019000067A1 (es) 2019-07-26
DOP2019000006A (es) 2019-03-31
MY190553A (en) 2022-04-27
DOP2021000026A (es) 2021-07-30
US11912757B2 (en) 2024-02-27
KR20190027382A (ko) 2019-03-14
EP3484915B1 (en) 2023-08-16
US20210363227A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
PL3484915T3 (pl) Nowe przeciwciała swoiście wiążące się z epitopami wirusa zika i ich zastosowania
IL271515A (en) Multispecific antibodies that specifically bind to Zika virus epitopes and their uses
ZA201903848B (en) Antibodies that specifically bind to human il-15 and uses thereof
ZA201906813B (en) Antibody binding specifically to muc1 and use thereof
IL268243A (en) Antibodies to alpha-synuclein and their uses
ZA201905341B (en) Antibodies specifically binding to human il-1r7
ZA201808582B (en) Antibodies to alpha-synuclein and uses thereof
SMT202600071T1 (it) Proteine leganti l'antigene anti-tl 1a e relativi usi
IL247221A0 (en) Antibodies that bind to the dengue virus, preparations containing them and their uses
PL2992010T3 (pl) Modyfikowane asymetryczne przeciwciała wiążące receptor Fc i sposoby ich stosowania
ZA201902120B (en) Antibody specifically binding to pd-1 and functional fragment thereof
IL269394A (en) Antibodies bind to STEAP-1
IL266516B (en) An antibody that specifically binds to cd66c and its use
SG10201912925SA (en) Antibodies that bind zika virus envelope protein and uses thereof
SG11201704500VA (en) Antibody binding to neuropilin 1 and use thereof
ZA201701941B (en) Antigen binding proteins that bind cxcr3
EP3225628A4 (en) Epitope of hepatitis b virus surface antigen and binding molecule specifically binding to same for neutralizing hepatitis b virus
GB201415714D0 (en) Antibodies and antigen binding fragments thereof
PL3362480T3 (pl) Przeciwciało specyficznie wiążące się z ERBB3 i jego zastosowanie
ZA202001042B (en) Antibody specifically binding to pauf protein, and use thereof
HK1234073A1 (en) Anti-hepatitis c antibodies and antigen binding fragments thereof